PMID- 23896581
OWN - NLM
STAT- MEDLINE
DCOM- 20140506
LR  - 20211021
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 9
IP  - 8
DP  - 2013 Aug
TI  - Immunogenicity and safety of three 2010-2011 seasonal trivalent influenza 
      vaccines in Chinese toddlers, children and older adults: a double-blind and 
      randomized trial.
PG  - 1725-34
LID - 10.4161/hv.24832 [doi]
AB  - The 2009 influenza A(H1N1) pandemic strain was for the first time included in the 
      2010-2011 seasonal trivalent influenza vaccine (TIV). We conducted a 
      double-blind, randomized trial in Chinese population to assess the immunogenicity 
      and safety of the 2010-2011 TIV manufactured by GlaxoSmithKline and compared it 
      with the counterpart vaccines manufactured by Sanofi Pasteur and Sinovac Biotech. 
      Healthy toddlers (6-36 mo), children (6-12 y) and older adults (>/=60 y) with 300 
      participants in each age group were enrolled to randomly receive two doses 
      (toddlers, 28 d apart) or one dose (children and older adults). The 
      immunogenicity was assessed by hemagglutination-inhibition (HI) assay. The 
      solicited injection-site and systemic adverse events (AEs) were collected within 
      7 d after vaccination. All the three TIVs were well-tolerated with 15.1% of 
      participants reporting AEs, most of which were mild. No serious AEs and unusual 
      AEs were reported. Fever and pain were the most common systemic and 
      injection-site AEs, respectively. The three TIVs showed good immunogenicity. The 
      seroprotection rates against both H1N1 and H3N2 strains were more than 87% in 
      toddlers after two doses and more than 95% in children and more than 86% in older 
      adults after one dose. The seroprotection rates against B strain were 68-71% in 
      toddlers after two doses, 70-74% in children and 69-72% in older adults after one 
      dose. In conclusion, the three 2010-2011 TIVs had good immunogenicity and safety 
      in Chinese toddlers, children and older adults and were generally comparable in 
      immunogenicity and reactogenicity.
FAU - Luo, Feng-Ji
AU  - Luo FJ
AD  - Beijing Chaoyang District Center for Disease Control and Prevention; Beijing, 
      P.R. China.
FAU - Yang, Li-Qing
AU  - Yang LQ
FAU - Ai, Xing
AU  - Ai X
FAU - Bai, Yun-Hua
AU  - Bai YH
FAU - Wu, Jiang
AU  - Wu J
FAU - Li, Shu-Ming
AU  - Li SM
FAU - Zhang, Zheng
AU  - Zhang Z
FAU - Lu, Min
AU  - Lu M
FAU - Li, Li
AU  - Li L
FAU - Wang, Zhao-Yun
AU  - Wang ZY
FAU - Shi, Nian-Min
AU  - Shi NM
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130604
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Antibodies, Viral)
RN  - 0 (Influenza Vaccines)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Viral/blood
MH  - Child
MH  - Child, Preschool
MH  - China/epidemiology
MH  - Double-Blind Method
MH  - Drug-Related Side Effects and Adverse Reactions/epidemiology/pathology
MH  - Female
MH  - Hemagglutination Inhibition Tests
MH  - Humans
MH  - Infant
MH  - Influenza A Virus, H1N1 Subtype/immunology
MH  - Influenza A Virus, H3N2 Subtype/immunology
MH  - Influenza B virus/immunology
MH  - Influenza Vaccines/administration & dosage/*adverse effects/*immunology
MH  - Influenza, Human/*epidemiology/*prevention & control
MH  - Male
MH  - Middle Aged
PMC - PMC3906273
OTO - NOTNLM
OT  - immunogenicity
OT  - influenza
OT  - influenza A (H1N1)
OT  - safety
OT  - seasonal trivalent influenza vaccine
OT  - vaccine
EDAT- 2013/07/31 06:00
MHDA- 2014/05/07 06:00
PMCR- 2014/08/01
CRDT- 2013/07/31 06:00
PHST- 2013/07/31 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2014/05/07 06:00 [medline]
PHST- 2014/08/01 00:00 [pmc-release]
AID - 24832 [pii]
AID - 2013HV0059R [pii]
AID - 10.4161/hv.24832 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2013 Aug;9(8):1725-34. doi: 10.4161/hv.24832. Epub 2013 
      Jun 4.